Centrus Energy Corp vs NeoGenomics Inc. Common Stock — how do they compare? Centrus Energy Corp trades at $116.35 (market cap $2.45B), while NeoGenomics Inc. Common Stock trades at $17 (market cap $2.17B). The key difference: Centrus Energy Corp and NeoGenomics Inc. Common Stock are close in size by market cap, and NeoGenomics Inc. Common Stock is trading nearer its 52-week high, Centrus Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Centrus Energy Corp for 31 Days and NeoGenomics Inc. Common Stock for 0 Days on average.
| LEU | NEO | |
|---|---|---|
Market Cap | $2.45B | $2.17B |
Volume | 1,447,414 | 1,615,943 |
Sector | Energy | Health |
52-Week High | $436.00 | $19.91 |
52-Week Low | $119.95 | $7.19 |
Typical Hold Time | 31 Days | 0 Days |
Enterprise Value | $1.76B | $2.47B |
Signals from Pluang's Aura AI — not financial advice
Centrus Energy (LEU) trades at $134.28, down 0.76% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows elevated valuation metrics with a P/E of 63.47 and P/S of 5.64, while profitability metrics remain solid with a 10.23% net income margin. Recent news highlights Centrus' strategic positioning as the only US-licensed producer of high-assay low-enriched uranium (HALEU), with multiple new supply contracts announced in September 2026.
The investment case hinges on execution of nuclear fuel contracts amid growing demand, but faces risks from high valuation and operational challenges. Analyst consensus remains positive with a $218.10 price target, though technical indicators suggest near-term pressure. The company's unique position in the nuclear supply chain offers growth potential, but requires careful monitoring of cash flow trends and contract execution.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Centrus Energy is a leading supplier of nuclear fuel and services for the global power industry. It specializes in supplying low-enriched uranium and developing next-generation fuels for advanced nuclear reactors.
Read more on LEU →NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →